Skip to main content
HealthReportedMediumDeveloping
4.7

Experimental drug daraxonrasib doubles survival in advanced pancreatic cancer trial

An international trial, with UChicago Medicine among U.S. sites, reports that the experimental drug daraxonrasib doubled average survival in patients with advanced pancreatic cancer. The finding is preliminary and not yet peer-reviewed or regulatory-approved, but it represents a notable potential advance against a disease with poor prognosis. Uncertainty remains on safety, durability, and whether the benefit extends beyond the studied subgroup.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

El Universoabout 19 hours agoUSCredibility 17%View source

Score Breakdown

Mosaic Score4.7
Model confidence0.5
Significance0.5
Source credibility0.2

Intelligence Tags

Locations

Chicago

Entities

United Statescountry
Source

Related signals

8 found